TNXP 8-K: SEC filing

Tonix Pharmaceuticals

Filed with the SEC on Nov 9, 2026 · accession 0001493152-26-050621

TNXP filed a 8-K (current report) with the SEC on Nov 9, 2026. A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.

Summary of the filing

Tonix Pharmaceuticals announced its operating results for the quarter ended September 30, 2026, via a press release filed as Exhibit 99.01 to this Form 8-K.

For details, click here →How to read a 8-K →

Key details

RegistrantTonix Pharmaceuticals Holding Corp.

Chief financial officerBradley Saenger

✦ Ask GOAX AI about this filing — what it means for TNXP, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for TNXP?

Click here

Frequently asked questions

What did TNXP file with the SEC on Nov 9, 2026?

TNXP filed a 8-K (SEC filing). Tonix Pharmaceuticals announced its operating results for the quarter ended September 30, 2026, via a press release filed as Exhibit 99.01 to this Form 8-K.

How do I read a 8-K?

A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The "Item" number tells you the topic (e.g. 2.02 results, 5.02 executive change, 1.01 new agreement, 1.03 bankruptcy). Exhibits (99.1 press release) usually hold the details.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 8-K (current report): A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.

Other TNXP SEC filings

Get alerts when TNXP files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days

TNXP overview TNXP analysis TNXP news Latest SEC filings